Clinical Research Directory

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate and no curative local therapy considered possible * Age ≥ 18 years, life expectancy of at least 6 months * CRPC defined as tumor progression (PSA increase on at least 2 separate values separated by at least 1 week or progression on imaging) while on Androgen Deprivation Therapy (orchiectomy, LHRH agonist or -antagonist) with documented serum testosterone levels ≤ 1.7 nmol/L (≤ 0.50 ng/mL). Ongoing concurrent use of LHRH agonist or antagonist is required if the patient has not been surgically castrated * Presence (M1) or absence (M0) of metastases on imaging * Performance status 0, 1 or 2 * No previous use of life- prolonging treatments for CRPC (including abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease is allowed. * Adequate renal function within 30 days prior to registration: calculated creatinine clearance ≥ 50 mL/min, according to the formula of Cockcroft-Gault and adequate liver function with levels of AST and ALT ≤ 3xULN and no signs for cholestasis. * Participation in other clinical trials is allowed except for trials with the same primary endpoint, i.e. OS * Patient authorized to participate to a clinical trial by specific country regulation (eg patient affiliated to a social security system or beneficiary of the same) * Information delivered to patient and informed consent form signed by the patient. Exclusion Criteria: * Previous localised malignancy within 2 years with the exception of localized non-melanoma skin cancer and Ta or Tis bladder cancer (patients with asymptomatic Chronic Lymphocytic Leukemia can be included) * Previous metastatic malignancy within 5 years * Patient currently taking daily acetylsalicylic acid or a daily statin within the last 6 months * Patients with active liver disease (hepatitis B or C, cirrhosis) or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal or cholestasis * Patients with excessive alcohol intake or history of a relevant liver disease * Known hypersensitivity or intolerance to acetylsalicylic acid or atorvastatin or hypersensitivity to any of its components * Contra-indication to acetylsalicylic acid or atorvastatin according to label, including known high-risk for haemorrhage, * History of or active myopathy or significantly elevated (\> 5 times ULN) CK levels * History of recent stroke or transient ischemic attack (TIA). * Any concomitant drugs contraindicated for use with the trial drugs according to the product information (e.g. Fusidic acid, potent inhibitors of CYP3A4 or transport proteins: ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir, telaprevir, saquinavir, darunavir, fosamprenavir, boceprevir, gemfibrozil, fenofibrate, etc) * Any serious underlying medical condition (by the investigator's judgement) which could impair the ability of the patient to participate in the trial * Patients with hereditary galactose intolerance, Lapp-lactase deficiency or Glucose-Galactose-malabsorption * Compliance with trial medical follow-up impossible due to geographic, social or psychological reasons * Psychiatric disorder precluding understanding of information about trial related topics, providing informed consent, or interfering with compliance for oral drug intake